Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling the end of the programme and ...

Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad, reducing their need for clinic visits. New guidance (PDF) from health ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Apple goes global with key MDM tools and services for business Free device management and deployment tools, additional services, and more are now more widely available as Apple grows an alternative to ...

There's no reason to ever be bored in Leicestershire, with a wide range of bars, restaurants and music venues, as well as a host of attractions and events for all the family ...